Announced nomination of RJVA-001 as first clinical candidate in the Rejuva® GLP-1 gene therapy platform; completion of IND- enabling studies expected in second half of 2024 Completed initial public of ering of common stock raising $110 million in gross proceeds; cash on hand expected to fund operations through 2025 BURLINGTON, MA, April 1, 2024 (GLOBENEWSWIRE) – Fractyl Health (Nasdaq: GUTS), a metabolic therapeutics company focused on pioneering new approaches for the treatment of type 2 diabetes (T2D) and ...

Table of Contents Registration No. 333-276046 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 to Index to Financial Statements FORM S-1 REGISTRATION STATEMENT UNDER As filed with the Securities and Exchange Commission on January 29, 2024. THE SECURITIES ACT OF 1933 FRACTYL HEALTH, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 3841 27-3553477 (Primary Standard Industrial Classificatio ...

Table of Contents Index to Financial Statements As filed with the Securities and Exchange Commission on December 14, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FRACTYL HEALTH, INC. Harith Rajagopalan, M.D., Ph.D. Chief Executive Officer Fractyl Health, Inc. 17 Hartwell Avenue Lexington, MA 02421 (781) 902-8800 (Name, address, including zip code, and telephone number, including area code, ...